Literature DB >> 31768852

A New Component in the Mechanism of Regulation of Endogenous Depressive-Like States.

T L Garibova1, T A Gudasheva2, S B Seredenin1.   

Abstract

It was shown previously that cycloprolylglycine, an endogenous neuropeptide, is a positive AMPA receptor modulator and is able to increase the content of BDNF in neurons. In the present study, using the model of learned helplessness in rats, we showed that cycloprolylglycine at a dose of 1 mg/kg at subchronic intraperitoneal administration reduced the time of animal immobility to passive control values (from 167.6 to 83.6 s) on day 12 of the experiment. This indicates the presence of antidepressant-like activity. The results of the study allow us to consider cycloprolylglycine as a component in the physiological regulation of the depression-like state.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31768852     DOI： 10.1134/S1607672919050107

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  14 in total

1.  [Novel endogenous dipeptide cycloprolyl-glycine is similar to pyracetam in selectivity of their mnemotropic effect].

Authors:  T A Gudasheva; R U Ostrovskaia; S S Trofimov; T A Voronina; A P Skoldinov; S B Seredenin
Journal:  Biull Eksp Biol Med       Date:  1999-10

2.  Pharmacokinetics of new nootropic acylprolyldipeptide and its penetration across the blood-brain barrier after oral administration.

Authors:  S S Boiko; R U Ostrovskaya; V P Zherdev; S A Korotkov; T A Gudasheva; T A Voronina; S B Seredenin
Journal:  Bull Exp Biol Med       Date:  2000-04       Impact factor: 0.804

3.  Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.

Authors:  T A Gudasheva; K N Koliasnikova; T A Antipova; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2016-09-07       Impact factor: 0.788

4.  Neuropeptide cycloprolylglycine is an endogenous positive modulator of AMPA receptors.

Authors:  T A Gudasheva; V V Grigoriev; K N Koliasnikova; V L Zamoyski; S B Seredenin
Journal:  Dokl Biochem Biophys       Date:  2017-01-06       Impact factor: 0.788

5.  Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs.

Authors:  Félicien Karege; Geneviève Vaudan; Michèle Schwald; Nader Perroud; Romano La Harpe
Journal:  Brain Res Mol Brain Res       Date:  2005-03-05

Review 6.  Stress-based animal models of depression: Do we actually know what we are doing?

Authors:  Xin Yin; Nuri Guven; Nikolas Dietis
Journal:  Brain Res       Date:  2016-09-20       Impact factor: 3.252

7.  Neuropeptide Cycloprolylglycine Exhibits Neuroprotective Activity after Systemic Administration to Rats with Modeled Incomplete Global Ischemia and in In Vitro Modeled Glutamate Neurotoxicity.

Authors:  P Yu Povarnina; K N Kolyasnikova; S V Nikolaev; T A Antipova; T A Gudasheva
Journal:  Bull Exp Biol Med       Date:  2016-03-29       Impact factor: 0.804

8.  "Behavioural despair" in rats and mice: strain differences and the effects of imipramine.

Authors:  R D Porsolt; A Bertin; M Jalfre
Journal:  Eur J Pharmacol       Date:  1978-10-01       Impact factor: 4.432

9.  Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1.

Authors:  Jian Guan; Peter Gluckman; Panzao Yang; Geoff Krissansen; Xueying Sun; Yongzhi Zhou; Jingyuan Wen; Gemma Phillips; Paul R Shorten; Chris D McMahon; Graeme C Wake; Wendy H K Chan; Mark F Thomas; April Ren; Steve Moon; Dong-Xu Liu
Journal:  Sci Rep       Date:  2014-03-17       Impact factor: 4.379

10.  Novel glutamatergic drugs for the treatment of mood disorders.

Authors:  Kyle Ab Lapidus; Laili Soleimani; James W Murrough
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-07       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.